SAN MATEO, CA -- (MARKET WIRE) -- October 31, 2006 -- SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN) today reported results for the third quarter ended September 30, 2006. For the third quarter 2006, revenues from the sale of ZADAXIN®, SciClone’s lead product, increased by 18% to $8,270,000, compared with $7,016,000 for the third quarter 2005. For the nine months ended September 30, 2006, revenues totaled $23,969,000, an increase of 17% compared with $20,528,000 for the same period of 2005. This increase in product revenues for the third quarter and nine months ended September 30, 2006 is primarily attributable to our expanded marketing efforts in China, leading to an increase in the quantity of ZADAXIN sold to the China market, which accounts for over 90% of overall ZADAXIN sales. Contract revenue for the third quarter 2006 was $26,000, compared with $134,000 for the third quarter 2005. For the nine months ended September 30, 2006, contract revenue was $170,000 compared with $402,000 for the same period of 2005.
